Yi Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yi Chen has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Xin He
Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital
6 shared publicationsZhengpeng Li
Microbiota Division, Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital
4 shared publications- Guanghui Li
Division of Endocrinology and Metabolism, Department of Obstetrics, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, No 251, Yaojiayuan Road, Chaoyang District, Beijing, 100026, China
3 shared publications - Liying Zou
Department of Obstetrics & Gynecology, Beijing Obstetrics and Gynecology Hospital, Beijing, 100006, China
3 shared publications - Weiyuan Zhang
Department of Obstetrics, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
3 shared publications Xiaohui Li
Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital
3 shared publications
Latest Publications
- Open Access
- 7 March 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 405, 121589
Heterogeneity in perinatal depression and its related factors: a longitudinal study in Beijing, China
- 7 March 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 405, 121589
Open AccessHeterogeneity in perinatal depression and its related factors: a longitudinal study in Beijing, China
- Open Access
- 1 March 2026
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 18, 1-15
Trajectories of Perinatal Depressive Symptoms from the Second Trimester to Three Months Postpartum and Their Dynamic Relationship with Social Support: A Prospective Cohort Study in Beijing, China
Purpose: Social support has long been recognised as one of the most important extrinsic factors influencing perinatal depressive symptoms, yet few cohort studies have simultaneously tracked changes in both domains. This study aimed to identify heterogeneous trajectories of depressive symptoms and to examine their dynamic association with social support across the perinatal period. Patients and Methods: A prospective cohort study was conducted in Beijing, enrolling participants at 15 gestational weeks. Depressive symptoms were assessed using the Edinburgh Postnatal Depression Scale (EPDS), and social support was measured with the Social Support Rating Scale (SSRS) at five time points from enrolment to three months postpartum. A total of 1416 women completed at least three assessments. The overall trajectory of depressive symptoms was estimated using LGCM, and LCGM was used to identify heterogeneous subgroups. The association between depressive symptoms and social support over time was examined using a parallel-process growth model. Results: The overall EPDS trajectory showed a progressive increase from mid-pregnancy to three months postpartum. Two latent trajectories were identified: an ascending–low symptom group (72.2%) with initially low but gradually increasing symptom levels, and a persistently elevated symptom group (27.8%) with persistently elevated symptoms. After accounting for social support, the overall trajectory flattened into a stabilized linear pattern. In subgroup analyses, higher symptom levels were observed in both groups in models not accounting for social support; notably, the formerly ascending–low symptom group transformed into a stable linear trajectory at a higher level. Conclusion: From 15 weeks of gestation to three months postpartum, perinatal depressive symptoms showed an overall increasing trend. However, substantial heterogeneity was observed: approximately 70% of women followed an ascending–low symptom trajectory, whereas about 30% exhibited persistently elevated symptoms with minimal change over time. Higher social support was associated with less worsening of depressive symptoms over the perinatal period, and this association appeared stronger during pregnancy than postpartum, particularly among women with lower initial symptom levels. These findings suggest that strengthening social support across pregnancy and the postpartum period may contribute to mitigating symptom worsening and promoting improved maternal mental health.
- 1 March 2026
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 18, 1-15
Open AccessTrajectories of Perinatal Depressive Symptoms from the Second Trimester to Three Months Postpartum and Their Dynamic Relationship with Social Support: A Prospective Cohort Study in Beijing, China
Purpose: Social support has long been recognised as one of the most important extrinsic factors influencing perinatal depressive symptoms, yet few cohort studies have simultaneously tracked changes in both domains. This study aimed to identify heterogeneous trajectories of depressive symptoms and to examine their dynamic association with social support across the perinatal period. Patients and Methods: A prospective cohort study was conducted in Beijing, enrolling participants at 15 gestational weeks. Depressive symptoms were assessed using the Edinburgh Postnatal Depression Scale (EPDS), and social support was measured with the Social Support Rating Scale (SSRS) at five time points from enrolment to three months postpartum. A total of 1416 women completed at least three assessments. The overall trajectory of depressive symptoms was estimated using LGCM, and LCGM was used to identify heterogeneous subgroups. The association between depressive symptoms and social support over time was examined using a parallel-process growth model. Results: The overall EPDS trajectory showed a progressive increase from mid-pregnancy to three months postpartum. Two latent trajectories were identified: an ascending–low symptom group (72.2%) with initially low but gradually increasing symptom levels, and a persistently elevated symptom group (27.8%) with persistently elevated symptoms. After accounting for social support, the overall trajectory flattened into a stabilized linear pattern. In subgroup analyses, higher symptom levels were observed in both groups in models not accounting for social support; notably, the formerly ascending–low symptom group transformed into a stable linear trajectory at a higher level. Conclusion: From 15 weeks of gestation to three months postpartum, perinatal depressive symptoms showed an overall increasing trend. However, substantial heterogeneity was observed: approximately 70% of women followed an ascending–low symptom trajectory, whereas about 30% exhibited persistently elevated symptoms with minimal change over time. Higher social support was associated with less worsening of depressive symptoms over the perinatal period, and this association appeared stronger during pregnancy than postpartum, particularly among women with lower initial symptom levels. These findings suggest that strengthening social support across pregnancy and the postpartum period may contribute to mitigating symptom worsening and promoting improved maternal mental health.
- Open Access
- 14 October 2025
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 38 (1) , 2567473
Placental transcriptomic profiling showed disturbance of chemokine activities and lymphocyte chemotaxis in pregnancy with fetal growth restriction
Fetal growth restriction (FGR) is a serious pathological complication associated with perinatal death and adverse pregnancy outcomes, which is largely related to placental dysfunction. This study aimed to identify FGR-related placenta transcriptomic features and provide insight into the pathologic mechanisms of FGR. In this research, transcriptomic data were obtained by RNA sequencing on placenta samples from eight FGR patients and eight normal term-pregnant women. Differential expression analysis was used to identify the differentially expressed genes (DEGs) between groups, then function and pathway enrichment analysis by DEGs was performed. After correlation analysis between DEGs and clinical indicators of FGR, validation of DEGs by Gene Expression Omnibus (GEO) dataset was carried out. Receiver operating characteristic (ROC) analysis was used to calculate the diagnostic ability of DEG biomarkers. We identified seven candidate DEGs. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed candidate DEGs primarily involved in chemokine activities and lymphocyte chemotaxis. Correlation analysis found that the expression level of DPPA4 and CTAG2 gene were significantly positively correlated with neonatal birth weight (p < 0.05). The expression level of IGSF21 was significantly negatively correlated with placenta weight, neonatal birth weight and neonatal birth weight percentile (p < 0.05). The expression level of CXCL11 showed a negative correlation with neonatal birth weight and neonatal birth weight percentile (p < 0.05). Additionally, the expression level of CXCL10 exhibited a negative correlation to neonatal birth weight percentile (p < 0.05). The expression level of HLA-DQA1, CXCL10 and CXCL11 in the GEO dataset were in good agreement with our results. We conducted the ROC analysis and found the area under the curve (AUC) values based on each DEG alone were 80% for HLA-DQA1, 79%f or CXCL11 and 76% for CXCL10, suggesting that the above three DEGs had potential significance for FGR diagnosis. This study gives an insight into transcriptional features in FGR mechanism and discovers novel genes that may provide evidence for predicting and managing FGR.
- 14 October 2025
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 38 (1) , 2567473
Open AccessPlacental transcriptomic profiling showed disturbance of chemokine activities and lymphocyte chemotaxis in pregnancy with fetal growth restriction
Fetal growth restriction (FGR) is a serious pathological complication associated with perinatal death and adverse pregnancy outcomes, which is largely related to placental dysfunction. This study aimed to identify FGR-related placenta transcriptomic features and provide insight into the pathologic mechanisms of FGR. In this research, transcriptomic data were obtained by RNA sequencing on placenta samples from eight FGR patients and eight normal term-pregnant women. Differential expression analysis was used to identify the differentially expressed genes (DEGs) between groups, then function and pathway enrichment analysis by DEGs was performed. After correlation analysis between DEGs and clinical indicators of FGR, validation of DEGs by Gene Expression Omnibus (GEO) dataset was carried out. Receiver operating characteristic (ROC) analysis was used to calculate the diagnostic ability of DEG biomarkers. We identified seven candidate DEGs. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed candidate DEGs primarily involved in chemokine activities and lymphocyte chemotaxis. Correlation analysis found that the expression level of DPPA4 and CTAG2 gene were significantly positively correlated with neonatal birth weight (p < 0.05). The expression level of IGSF21 was significantly negatively correlated with placenta weight, neonatal birth weight and neonatal birth weight percentile (p < 0.05). The expression level of CXCL11 showed a negative correlation with neonatal birth weight and neonatal birth weight percentile (p < 0.05). Additionally, the expression level of CXCL10 exhibited a negative correlation to neonatal birth weight percentile (p < 0.05). The expression level of HLA-DQA1, CXCL10 and CXCL11 in the GEO dataset were in good agreement with our results. We conducted the ROC analysis and found the area under the curve (AUC) values based on each DEG alone were 80% for HLA-DQA1, 79%f or CXCL11 and 76% for CXCL10, suggesting that the above three DEGs had potential significance for FGR diagnosis. This study gives an insight into transcriptional features in FGR mechanism and discovers novel genes that may provide evidence for predicting and managing FGR.
- 10 April 2025
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 113 (2) , 410-422
Placental transcriptomic profiling in a mouse model of fetal growth restriction reveals disturbed inflammation and immunity regulation
To date, few studies have specifically explored the placental transcriptome of an animal model of fetal growth restriction (FGR) with nitric oxide (NO) deficiency. The aim of this study was to use NG-nitro-L-arginine methyl ester (L-NAME) to establish a mouse model of FGR with NO deficiency and explore the histological changes and the transcriptomic complexity of the placenta. We established a FGR mouse model via L-NAME administration (n = 6 per group). We assessed the biometric phenotypes of the fetuses and the placentas and analyzed placental and cellular morphology to confirm the pathological changes that occur in FGR placentas. Finally, we applied RNA-seq to analyze the placental transcriptome from the L-NAME-induced mouse model of FGR. We established a mouse model of FGR using L-NAME with biometric and pathological changes. Transcriptomic analysis identified eight differentially expressed genes (DEGs) between the FGR-affected and normal placentas, including six upregulated genes (solute carrier family 6 (neurotransmitter transporter), member 14 (Slc6a14), matrix metallopeptidase 9 (Mmp9), RAS guanyl releasing protein 1 (Rasgrp1), ATP-binding cassette, subfamily B member 1B (Abcb1b), solute carrier family 16 (monocarboxylic acid transporters), member 12 (Slc16a12), and transmembrane protein 255A (Tmem255a)) and two downregulated genes (protein tyrosine phosphatase receptor type N polypeptide 2 (Ptprn2) and meiosis 1 associated protein (M1ap)). These DEGs are highly involved in angiogenesis, the immune system, and inflammatory signaling pathways, underscoring the multifaceted nature of FGR pathology. This study contributes to the understanding of FGR pathophysiology, emphasizing the importance of the immune-related molecular markers and offering potential targets for therapeutic intervention.
- 10 April 2025
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 113 (2) , 410-422
Placental transcriptomic profiling in a mouse model of fetal growth restriction reveals disturbed inflammation and immunity regulation
To date, few studies have specifically explored the placental transcriptome of an animal model of fetal growth restriction (FGR) with nitric oxide (NO) deficiency. The aim of this study was to use NG-nitro-L-arginine methyl ester (L-NAME) to establish a mouse model of FGR with NO deficiency and explore the histological changes and the transcriptomic complexity of the placenta. We established a FGR mouse model via L-NAME administration (n = 6 per group). We assessed the biometric phenotypes of the fetuses and the placentas and analyzed placental and cellular morphology to confirm the pathological changes that occur in FGR placentas. Finally, we applied RNA-seq to analyze the placental transcriptome from the L-NAME-induced mouse model of FGR. We established a mouse model of FGR using L-NAME with biometric and pathological changes. Transcriptomic analysis identified eight differentially expressed genes (DEGs) between the FGR-affected and normal placentas, including six upregulated genes (solute carrier family 6 (neurotransmitter transporter), member 14 (Slc6a14), matrix metallopeptidase 9 (Mmp9), RAS guanyl releasing protein 1 (Rasgrp1), ATP-binding cassette, subfamily B member 1B (Abcb1b), solute carrier family 16 (monocarboxylic acid transporters), member 12 (Slc16a12), and transmembrane protein 255A (Tmem255a)) and two downregulated genes (protein tyrosine phosphatase receptor type N polypeptide 2 (Ptprn2) and meiosis 1 associated protein (M1ap)). These DEGs are highly involved in angiogenesis, the immune system, and inflammatory signaling pathways, underscoring the multifaceted nature of FGR pathology. This study contributes to the understanding of FGR pathophysiology, emphasizing the importance of the immune-related molecular markers and offering potential targets for therapeutic intervention.
- Open Access
- 30 October 2023
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology: X
- Vol. 20, 100259
Biomarker screening in fetal growth restriction based on multiple RNA-seq studies
- 30 October 2023
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology: X
- Vol. 20, 100259
Open AccessBiomarker screening in fetal growth restriction based on multiple RNA-seq studies
- Open Access
- 2 August 2022
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 71 (1) , 103354
The fecal microbiota of gravidas with fetal growth restriction newborns characterized by metagenomic sequencing
- 2 August 2022
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 71 (1) , 103354
Open AccessThe fecal microbiota of gravidas with fetal growth restriction newborns characterized by metagenomic sequencing
- 1 September 2021
- Published by Elsevier in Science of The Total Environment
- Vol. 787, 147604
PM2.5 exposure exaggerates the risk of adverse birth outcomes in pregnant women with pre-existing hyperlipidemia: Modulation role of adipokines and lipidome
- 1 September 2021
- Published by Elsevier in Science of The Total Environment
- Vol. 787, 147604
PM2.5 exposure exaggerates the risk of adverse birth outcomes in pregnant women with pre-existing hyperlipidemia: Modulation role of adipokines and lipidome
- 11 January 2021
- Published by Springer Nature in Reproductive Sciences
- Vol. 28 (7) , 2012-2022
The Effect and Mechanism of Asymmetric Dimethylarginine Regulating Trophoblastic Autophagy on Fetal Growth Restriction
Fetal growth restriction (FGR) is an important cause of perinatal death and adverse pregnancy outcomes. Asymmetric dimethylarginine (ADMA) is associated with FGR, but the mechanisms have not been thoroughly studied. Here, we determined the levels of ADMA and autophagy-related molecules in human blood samples and placental tissues. And we also used the human chorionic carcinoma cell line BeWo to investigate the mechanism of ADMA-induced FGR in vitro. Compared with the control group, ADMA levels in maternal blood and placenta were increased in patients with FGR, and the birth weight (BW) percentile was negatively correlated with maternal serum ADMA concentration in the FGR group. The expression of mammalian target of rapamycin (mTOR) in the placenta of the FGR group was lower than the control group, while the expression of Beclin-1 and microtubule-associated protein 1 light chain 3-II (LC3-II)/LC3-I was significantly increased in the FGR group. And the expression of matrix metalloproteinase 9 (MMP9) was decreased in the placenta of patients with FGR. In in vitro cell experiments, compared with the control group, the expression of mTOR and MMP9 in BeWo cells was decreased and the expression of Beclin-1 and LC3-II/LC3-I was increased in the ADMA-treated group. Moreover, ADMA had favorable effects on the formation of autophagic vacuoles, and the autophagy inhibitor 3-Methyladenine (3-MA) could reduce the autophagy-induction effect of ADMA on BeWo cells. This study found that ADMA could participate in the occurrence of FGR through inducing autophagy in trophoblasts.
- 11 January 2021
- Published by Springer Nature in Reproductive Sciences
- Vol. 28 (7) , 2012-2022
The Effect and Mechanism of Asymmetric Dimethylarginine Regulating Trophoblastic Autophagy on Fetal Growth Restriction
Fetal growth restriction (FGR) is an important cause of perinatal death and adverse pregnancy outcomes. Asymmetric dimethylarginine (ADMA) is associated with FGR, but the mechanisms have not been thoroughly studied. Here, we determined the levels of ADMA and autophagy-related molecules in human blood samples and placental tissues. And we also used the human chorionic carcinoma cell line BeWo to investigate the mechanism of ADMA-induced FGR in vitro. Compared with the control group, ADMA levels in maternal blood and placenta were increased in patients with FGR, and the birth weight (BW) percentile was negatively correlated with maternal serum ADMA concentration in the FGR group. The expression of mammalian target of rapamycin (mTOR) in the placenta of the FGR group was lower than the control group, while the expression of Beclin-1 and microtubule-associated protein 1 light chain 3-II (LC3-II)/LC3-I was significantly increased in the FGR group. And the expression of matrix metalloproteinase 9 (MMP9) was decreased in the placenta of patients with FGR. In in vitro cell experiments, compared with the control group, the expression of mTOR and MMP9 in BeWo cells was decreased and the expression of Beclin-1 and LC3-II/LC3-I was increased in the ADMA-treated group. Moreover, ADMA had favorable effects on the formation of autophagic vacuoles, and the autophagy inhibitor 3-Methyladenine (3-MA) could reduce the autophagy-induction effect of ADMA on BeWo cells. This study found that ADMA could participate in the occurrence of FGR through inducing autophagy in trophoblasts.
- 1 November 2020
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 204, 105752
Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome
- 1 November 2020
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 204, 105752
Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome
- 21 May 2020
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 27 (23) , 29280-29290
The impact of prenatal exposure to PM2.5 on childhood asthma and wheezing: a meta-analysis of observational studies
With the accelerated pace of economic development and modernization, air pollution has become one of the most focused public health problems. However, the impact of particulate matter exposure during pregnancy on childhood asthma and wheezing remains controversial. We performed this meta-analysis to explore the relationship between prenatal exposure to PM2.5 and childhood asthma and wheezing. Candidate papers were searched on PubMed, Web of Science, Embase, and Cochrane Library before July 15, 2019. The main characteristics of the included studies were extracted, and the quality was evaluated by the Newcastle–Ottawa Scale (NOS). A sensitivity analysis was performed to assess the impact of individual studies on the combined effects. The Egger and Begg tests were conducted to examine the publication bias. Nine studies were included in the final analysis. Prenatal exposure to PM2.5 significantly increased the risk of childhood asthma and wheezing (OR = 1.06, 95% CI 1.02–1.11; per 5 μg/m3). Maternal exposure was more strongly related to childhood asthma and wheezing before age 3 (OR = 1.15, 95% CI 1.00–1.31; per 5 μg/m3) than after (OR = 1.04, 95% CI 1.00–1.09; per 5 μg/m3). Children in developed countries showed more severe effects (OR = 1.14, 95% CI 1.02–1.27; per 5 μg/m3). Children who were born to mothers with higher levels of prenatal exposure were at higher risk of asthma and wheezing (OR = 1.07, 95% CI 1.02–1.13; per 5 μg/m3). This meta-analysis indicated that the impact of PM2.5 on childhood asthma and wheezing begins as early as utero, so regulating pollutant emission standards and strengthening prenatal protection are crucial to maternal and child health.
- 21 May 2020
- Published by Springer Nature in Environmental Science and Pollution Research
- Vol. 27 (23) , 29280-29290
The impact of prenatal exposure to PM2.5 on childhood asthma and wheezing: a meta-analysis of observational studies
With the accelerated pace of economic development and modernization, air pollution has become one of the most focused public health problems. However, the impact of particulate matter exposure during pregnancy on childhood asthma and wheezing remains controversial. We performed this meta-analysis to explore the relationship between prenatal exposure to PM2.5 and childhood asthma and wheezing. Candidate papers were searched on PubMed, Web of Science, Embase, and Cochrane Library before July 15, 2019. The main characteristics of the included studies were extracted, and the quality was evaluated by the Newcastle–Ottawa Scale (NOS). A sensitivity analysis was performed to assess the impact of individual studies on the combined effects. The Egger and Begg tests were conducted to examine the publication bias. Nine studies were included in the final analysis. Prenatal exposure to PM2.5 significantly increased the risk of childhood asthma and wheezing (OR = 1.06, 95% CI 1.02–1.11; per 5 μg/m3). Maternal exposure was more strongly related to childhood asthma and wheezing before age 3 (OR = 1.15, 95% CI 1.00–1.31; per 5 μg/m3) than after (OR = 1.04, 95% CI 1.00–1.09; per 5 μg/m3). Children in developed countries showed more severe effects (OR = 1.14, 95% CI 1.02–1.27; per 5 μg/m3). Children who were born to mothers with higher levels of prenatal exposure were at higher risk of asthma and wheezing (OR = 1.07, 95% CI 1.02–1.13; per 5 μg/m3). This meta-analysis indicated that the impact of PM2.5 on childhood asthma and wheezing begins as early as utero, so regulating pollutant emission standards and strengthening prenatal protection are crucial to maternal and child health.